GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NuVasive Inc (NAS:NUVA) » Definitions » Return-on-Tangible-Asset

NuVasive (NuVasive) Return-on-Tangible-Asset : 2.24% (As of Jun. 2023)


View and export this data going back to 2004. Start your Free Trial

What is NuVasive Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. NuVasive's annualized Net Income for the quarter that ended in Jun. 2023 was $29 Mil. NuVasive's average total tangible assets for the quarter that ended in Jun. 2023 was $1,318 Mil. Therefore, NuVasive's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 was 2.24%.

The historical rank and industry rank for NuVasive's Return-on-Tangible-Asset or its related term are showing as below:

NUVA' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -4.05   Med: 2.21   Max: 9.77
Current: 2.1

During the past 13 years, NuVasive's highest Return-on-Tangible-Asset was 9.77%. The lowest was -4.05%. And the median was 2.21%.

NUVA's Return-on-Tangible-Asset is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -2.53 vs NUVA: 2.10

NuVasive Return-on-Tangible-Asset Historical Data

The historical data trend for NuVasive's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NuVasive Return-on-Tangible-Asset Chart

NuVasive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 6.47 -2.39 -3.93 3.02

NuVasive Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.27 -0.59 6.97 -0.29 2.24

Competitive Comparison of NuVasive's Return-on-Tangible-Asset

For the Medical Devices subindustry, NuVasive's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NuVasive's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NuVasive's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where NuVasive's Return-on-Tangible-Asset falls into.



NuVasive Return-on-Tangible-Asset Calculation

NuVasive's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=40.407/( (1277.933+1400.553)/ 2 )
=40.407/1339.243
=3.02 %

NuVasive's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=29.456/( (1354.127+1281.274)/ 2 )
=29.456/1317.7005
=2.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Jun. 2023) net income data.


NuVasive  (NAS:NUVA) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


NuVasive Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of NuVasive's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


NuVasive (NuVasive) Business Description

Traded in Other Exchanges
N/A
Address
12101 Airport Way, Broomfield, CO, USA, 92121
NuVasive Inc is a medical technology company focused on developing, manufacturing, selling and providing procedural solutions for spine surgery, with a guiding purpose to transform surgery, advance care and change lives. The company has a portfolio of procedurally integrated spine surgery solutions, including surgical access instruments, spinal implants, fixation systems, biologics, and enabling technologies, as well as systems and services for intraoperative neuromonitoring. It also develop and sell magnetically adjustable implant systems for spine and specialized orthopedic procedures.
Executives
Michael Farrington officer: SVP, People and Culture 7475 LUSK BLVD., SAN DIEGO CA 92121
Marc W. Rosenbaum officer: Chief Accounting Officer 7475 LUSK BLVD., SAN DIEGO CA 92121
James Christopher Barry director, officer: Chief Executive Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Andrew C. Morton officer: SVP, CHRO 10910 DOMAIN DRIVE, SUITE 300, AUSTIN TX 78758
Amy Belt Raimundo director ONE KAISER PLAZA, 22ND FLOOR, OAKLAND CA 94612
Lucas Vitale officer: Chief Human Resources Officer 7475 LUSK BLVD, SAN DIEGO CA 92121
Massimo Calafiore officer: EVP, Global Business Units 7475 LUSK BLVD., SAN DIEGO CA 92121
Siddhartha Kadia director 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Vickie L Capps director 2985 SCOTT STREET, VISTA CA 92083
Brent J. Boucher officer: EVP, Global Commercial 14 PLAZA DRIVE, LATHAM NY 12110
Matthew Link officer: Exec. VP U.S. Sales 7475 LUSK BLVD, SAN DIEGO CA 92121
Matthew K Harbaugh officer: EVP and CFO 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Dale A. Wolf officer: SVP, Global Operations 7475 LUSK BLVD., SAN DIEGO CA 92121
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Paul Mcclintock officer: President, U.S. Commercial 7475 LUSK BLVD, SAN DIEGO CA 92121